Healthcare Industry News:  Transdermal 

Biopharmaceuticals FDA

 News Release - July 13, 2006

Nuvo's Pennsaid NDA Resubmission Accepted for Review by U.S. FDA

MISSISSAUGA, ON, July 13 (HSMN NewsFeed) - Nuvo Research Inc. (TSX:NRI ) today announced that it has resubmitted its New Drug Application (NDA) for Pennsaid®, a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis of the knee to the U.S. Food and Drug Administration (FDA). The FDA has confirmed that it has received Nuvo's resubmission for review and has indicated that its goal date to complete its review of the resubmission is December 28, 2006. The resubmission is a complete Class 2 response to the deficiencies outlined in an August 2002 Non-Approvable (NA) letter issued by the FDA with respect to Pennsaid®. Pennsaid® is currently approved for sale in Canada and several European countries.

"This resubmission is the result of significant efforts by our employees, management and our FDA advisory board," said Dr. Henrich Guntermann, Nuvo's President and CEO. "This NDA resubmission contains data collected from recent efficacy and safety trials that were designed to answer the FDA's key concerns. If approved, Pennsaid® will fill a major unmet need in the $3.7 billion U.S. osteoarthritis market."

To meet the FDA's clinical efficacy and safety requirements as stated in the NA letter, Nuvo conducted study 112, a 12-week Phase III, 5-arm, double-blind trial of 775 patients. This trial enrolled patients in the U.S. and Canada with symptoms of primary osteoarthritis of the knee. The trial met all of its primary endpoints, being pain, physical function and patient overall health assessment. The trial also demonstrated comparable efficacy of Pennsaid® to oral diclofenac.

To address the long-term safety requirements as stated in the NA letter, Nuvo conducted study 112E, a long-term multi-centre, single-arm safety study of Pennsaid® applied by patients with symptoms of osteoarthritis (OA) of the knee. In total, 793 patients were treated, including 448 patients for at least six months and 116 patients for at least one year. The key observation was that long-term use did not cause any new, unexpected adverse events.

About Nuvo Research Inc.

Nuvo is focused on developing innovative site-specific therapeutics that are delivered topically using the Company's skin-penetrating technologies. Nuvo's lead product is Pennsaid®, a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of Transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany. For more information, please visit www.nuvoresearch.com.

This release may contain forward-looking statements, subject to risks and uncertainties beyond management's control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Company's annual information form filed with the securities commissions in each of the provinces of Canada. The Company undertakes no obligation to revise forward-looking statements in light of future events.


Source: Nuvo Research

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.